Bacterial infection treatment developer Spero Therapeutics has filed to raise up to $86.3m in an initial public offering that will enable a host of corporates to exit.
Spero Therapeutics, a US-based bacterial infection therapy developer backed by internet and technology group Alphabet and several corporates in the healthcare sector, has filed for an $86.3m initial public offering.
Founded in 2013, Spero is developing therapeutics, some based on its Potentiator Platform technology, which will enhance the potency of existing antibiotics in order to treat bacterial infections that have proven resistant to multiple drugs.
The proceeds will fund a phase 1 clinical trial and the initiation of a phase…
